Medical technology

Smisson-Cartledge Biomedical, LLC Announces John E. Hart as President and Chief Executive Officer

Retrieved on: 
Thursday, June 24, 2021
Biotechnology, Medical Supplies, Surgery, General Health, Health, Medical devices, Hospitals, Other Health, Medical technology, Companies, Medical devices, Stryker Corporation, Medtronic, Covidien, Stryker, ISO 13485

Smisson-Cartledge Biomedical LLC, an ISO 13485:2016 certified manufacturer of the ThermaCor 1200 Rapid Infuser technology for use in a broad spectrum of medical procedures, today announced that John E Hart has been named as President and Chief Executive Officer to lead the company.

Key Points: 
  • Smisson-Cartledge Biomedical LLC, an ISO 13485:2016 certified manufacturer of the ThermaCor 1200 Rapid Infuser technology for use in a broad spectrum of medical procedures, today announced that John E Hart has been named as President and Chief Executive Officer to lead the company.
  • Prior to that he served as Chief Operating Office for ISTO Technologies, Inc. for 3 years and President and CEO of Vidar Systems Corporation for 5 years.
  • John is the right leader for Smisson-Cartledge Biomedical, said Hugh F. Smisson, III M.D., SCBs Chairman of the Board.
  • John has also held senior executive positions in Fortune 500 companies, including Stryker Orthopaedics (Stryker Corporation) and U.S. Surgical (Covidien now Medtronic).

Oticon Medical Announces FDA Premarket Approval for Neuro Cochlear Implant System to Treat Severe to Profound Sensorineural Hearing Loss

Retrieved on: 
Thursday, June 24, 2021
Consumer electronics, Health, FDA, Medical devices, Technology, Other Health, Audio, Video, Medical technology, Audiology, Otology, Branches of biology, Health sciences, Medical devices, Hearing loss, Cochlear implant, Implant, Cochlear, Sensorineural hearing loss, Cochlear Bone Anchored Solutions

With the expansion of its cochlear implant solutions to the US market, Oticon Medical is well positioned to become the worlds leading hearing expert within implantable hearing solutions.

Key Points: 
  • With the expansion of its cochlear implant solutions to the US market, Oticon Medical is well positioned to become the worlds leading hearing expert within implantable hearing solutions.
  • People with severe to profound hearing loss in 51 countries already benefit from the Neuro System.
  • View the full release here: https://www.businesswire.com/news/home/20210624005685/en/
    Oticon Medical announces that the US Food and Drug Administration (FDA) has granted Premarket Approval (PMA) for the Neuro Cochlear Implant System to treat severe to profound sensorineural hearing loss.
  • The Neuro System is the first new cochlear implant technology to earn FDA premarket approval in more than 20 years.

Stimwave Technologies Provides Business Update

Retrieved on: 
Thursday, June 24, 2021
Biotechnology, General Health, Health, Medical devices, Medical technology, Biomedical engineering, Implant, Prosthetics, Tissue engineering, Medical device, Micron Technology, Technology, Biotechnology

Stimwave Technologies Incorporated, a global medical device company that provides minimally invasive, MRI-compatible implantable devices to treat chronic pain for more patients, today provided a business update.

Key Points: 
  • Stimwave Technologies Incorporated, a global medical device company that provides minimally invasive, MRI-compatible implantable devices to treat chronic pain for more patients, today provided a business update.
  • We are excited to announce that Stimwave Technologies has prevailed in the challenge by Micron Devices LLC (Micron) regarding the Companys ownership of its intellectual property, StimQ Medical LLC subsidiary equity, and various other assets.
  • Within the last year, the Company has added significantly to key areas of the business including, compliance, quality, regulatory, accounting, legal, manufacturing operations, R&D and medical education.
  • Stimwave Technologies Incorporated is a privately held medical device company engaged in the development, manufacture, commercialization of wirelessly powered, injectable, microtechnology neurostimulators.

Arkansas Neurosurgeon Successfully Implants His 400th ENZA-A Titanium ALIF Implant

Retrieved on: 
Wednesday, June 23, 2021
Surgery, Health, Medical devices, Medical specialties, Medicine, Medical technology, Prosthetics, Biomaterials, Biomedical engineering, Implant, Tissue engineering, Titanium, Neurosurgery, Alif, Spine

Camber Spine , a leading innovator in spine and medical technologies, has announced that Dr. James B. Blankenship, MD, a neurosurgical specialist practicing at the Neurosurgery Spine Center in Fayetteville, Arkansas, has now successfully implanted his 400th ENZA-A Titanium ALIF implant.

Key Points: 
  • Camber Spine , a leading innovator in spine and medical technologies, has announced that Dr. James B. Blankenship, MD, a neurosurgical specialist practicing at the Neurosurgery Spine Center in Fayetteville, Arkansas, has now successfully implanted his 400th ENZA-A Titanium ALIF implant.
  • Camber Spines ENZA-A ALIF implant is an all titanium, 3D-printed construct with inferior and superior surfaces specifically designed with a controlled, trabecular pattern to create an environment for fusion to occur.
  • And the ENZA-A implant is by far the best implant I have used.
  • The ENZA-A Titanium ALIF can be inserted, deployed and locked all through the in-line instrumentation of the inserter, which reduces complexity and surgery time.

Second Sight Medical Products Announces Pricing of Public Offering

Retrieved on: 
Wednesday, June 23, 2021
General Health, Optical, Health, Medical devices, Medical technology, Biomedical engineering, Biotechnology, Technology, Prosthetics, Neuroprosthetics, Emerging technologies, Medical devices, Visual prosthesis, Second Sight, Implant, Prosthesis, the Orion Visual Cortical Prosthesis System, Second Sight Medical Products, Inc., THE ORION VISUAL CORTICAL PROSTHESIS SYSTEM, SECOND SIGHT MEDICAL PRODUCTS, INC.

Second Sight Medical Products, Inc. (NASDAQ: EYES) (Second Sight or the Company), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and other offering expenses.

Key Points: 
  • Second Sight Medical Products, Inc. (NASDAQ: EYES) (Second Sight or the Company), a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced the pricing of its underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $5.00 per share, for gross proceeds of $50,000,000, before deducting underwriting discounts, commissions and other offering expenses.
  • ThinkEquity, a division of Fordham Financial Management, Inc., is acting as sole book-running manager for the offering.
  • The Company intends to use the net proceeds from the offering primarily for development of the Orion device and general corporate purposes.
  • About Second Sight Medical Products, Inc.
    Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.

Second Sight Medical Products Announces Proposed Public Offering of Common Stock

Retrieved on: 
Tuesday, June 22, 2021
Optical, Health, Other Health, Medical devices, Medical technology, Prosthetics, Technology, Biotechnology, Biomedical engineering, Emerging technologies, Medical devices, Visual prosthesis, NASDAQ, Prosthesis, Implant, Second Sight, the Orion Visual Cortical Prosthesis System, Second Sight Medical Products, Inc., THE ORION VISUAL CORTICAL PROSTHESIS SYSTEM, SECOND SIGHT MEDICAL PRODUCTS, INC.

Second Sight Medical Products, Inc. (NASDAQ: EYES) (Second Sight or the Company) a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering.

Key Points: 
  • Second Sight Medical Products, Inc. (NASDAQ: EYES) (Second Sight or the Company) a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, today announced that it intends to offer to sell shares of its common stock in an underwritten public offering.
  • All of the shares of common stock are to be sold by the Company.
  • The Company intends to use the net proceeds from the offering primarily for development of the Orion device and general corporate purposes.
  • About Second Sight Medical Products, Inc.
    Second Sight Medical Products, Inc. (Nasdaq: EYES) develops implantable visual prosthetics that are intended to deliver useful artificial vision to blind individuals.

Supersapiens Powered by Abbott’s Libre Sense Glucose Sport Biosensor Announces Garmin Integration

Retrieved on: 
Tuesday, June 22, 2021
Medicine, Diabetes, Medical technology, Medical monitoring, Clinical medicine, Continuous glucose monitor, Blood tests, Blood glucose monitoring, Biosensor, Blood sugar level, CGM, Libre

Atlanta, GA, USA, June 22, 2021 (GLOBE NEWSWIRE) -- Supersapiens, powered by Abbotts Libre Sense Glucose Sport Biosensor, is announcing its initial integration of the Supersapiens Connect IQ app with Garmin.

Key Points: 
  • Atlanta, GA, USA, June 22, 2021 (GLOBE NEWSWIRE) -- Supersapiens, powered by Abbotts Libre Sense Glucose Sport Biosensor, is announcing its initial integration of the Supersapiens Connect IQ app with Garmin.
  • A partnership with global healthcare leader Abbott makes Supersapiens the only energy management ecosystem that directly integrates with a Bluetooth-enabled sports continuous glucose monitor (CGM) the Abbott Libre Sense Glucose Sport Biosensor.
  • We brought the Supersapiens app, powered by Abbotts Libre Sense, to market six months ago with the goal of providing athletes with live visibility of their glucose levels during exercise.
  • The Abbott Libre Sense Glucose Sport Biosensor is intended for athletes to measure glucose.

Women Who Tech Launches First Global FemTech and HealthTech Program to Fund Women-Led Startups Driving the Future of Healthcare

Retrieved on: 
Tuesday, June 22, 2021
Femtech, Medical technology, Women's health, Startup company

To help fund the future of innovation - by women for women - while spurring more cutting-edge advancements, Women Who Tech is deploying capital and resources to FemTech and HealthTech startups working to champion greater healthcare access on a global scale, bolstering the medical tech ecosystems, and bringing more effective digital health solutions and technologies to market.

Key Points: 
  • To help fund the future of innovation - by women for women - while spurring more cutting-edge advancements, Women Who Tech is deploying capital and resources to FemTech and HealthTech startups working to champion greater healthcare access on a global scale, bolstering the medical tech ecosystems, and bringing more effective digital health solutions and technologies to market.
  • Five early-stage women-led startups with a focus on FemTech and/or HealthTech will be selected to compete for $20,000 USD in equity-free grant funding.
  • The W Fund, SteelSky Ventures, Citrine Angels, and others will also be evaluating the startups for further investment.
  • Women Who Tech's FemTech and HealthTech Grants Challenge is bolstering support for global healthcare and digital solutions with grants, fundraising and investing support, and more.

CoreLink Announces FDA Clearance of F3D Corpectomy System

Retrieved on: 
Tuesday, June 22, 2021
Prosthetics, Branches of biology, Biomedical engineering, Implant, Tissue engineering, Trabecula, Bone, Douglas F3D Skyknight, Medical technology, Biology

ST. LOUIS, June 22, 2021 /PRNewswire/ -- CoreLink, LLC , a leading designer and manufacturer of spinal implant systems, today announced the commercial launch and 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the F3D Corpectomy VBR System .

Key Points: 
  • ST. LOUIS, June 22, 2021 /PRNewswire/ -- CoreLink, LLC , a leading designer and manufacturer of spinal implant systems, today announced the commercial launch and 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the F3D Corpectomy VBR System .
  • The F3D Corpectomy System is designed with porous endplates and a trabecular structure lining the interior of the device, which may allow for direct bony attachment and bone formation throughout the device.
  • "This latest addition to our F3D portfolio provides a better solution for surgeons that perform these difficult corpectomy and vertebrectomy procedures.
  • Our continued investment in this technology platform brings this system to the forefront of the industry," said Jay Bartling, CEO of CoreLink.

Sky Medical Technology wins Liverpool Echo Regional Business Award 2021

Retrieved on: 
Friday, June 18, 2021
Medtech, Health care, Zimmer Biomet Robotics, Health, National Health Service, HIR, Health technology, Daresbury, Medical technology

Sky Medical Technology has partnered with clinicians across the NHS and private medical facilities to improve patient outcomes and is exploring further use cases for its technology.

Key Points: 
  • Sky Medical Technology has partnered with clinicians across the NHS and private medical facilities to improve patient outcomes and is exploring further use cases for its technology.
  • LONDON, June 18, 2021 /PRNewswire/ -- Daresbury (Cheshire) based medical technology (MedTech) company, Sky Medical Technology (Sky), has won the Innovation and Technology Award at the Liverpool Echo Regional Business Awards 2021.
  • Sky Medical Technology is addressing some of the most serious life-threatening and limiting illnesses that impact people's lives through innovative and non-invasive technology.
  • Sky Medical Technology is a highly innovative UK-based medical devices company that has developed a ground-breaking neuromuscular electrostimulation technology platform, OnPulse.